Volume 3.20 | May 22

Hematopoiesis News 3.20, May 22, 2012
Hematopoiesis News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Generation of Induced Pluripotent Stem Cells from Primary Chronic Myelogenous Leukemia Patient Samples
Researchers found that chronic myelogenous leukemia (CML)-induced pluripotent stem cell-derived hematopoietic cells recovered the sensitivity to imatinib although CD34+3890+45+ immature cells were resistant to imatinib, which recapitulated the pathophysiological feature of the initial CML. [Blood] Abstract

Got Paper? Use StemLab™ Visit us at ISCT, booth #210 or schedule a demo
PUBLICATIONS (Ranked by Impact Factor of the Journal)


Osteoblastic N-Cadherin Is Not Required for Microenvironmental Support and Regulation of Hematopoietic Stem and Progenitor Cells
To determine if osteoblastic N-cadherin is required for hematopoietic stem cell regulation, researchers employed a genetic murine model in which deletion of Cdh2, the gene encoding N-cadherin, has been targeted to cells of the osteoblastic lineage. [Blood] Abstract

CD62L Memory T Cells Enhance T-Cell Regeneration after Allogeneic Stem Cell Transplantation by Eliminating Host Resistance in Mice

Researchers investigated how CD62L T cells contributed to phenotypic and functional T cell reconstitution post allogeneic hematopoietic cell transplantation. The data further highlight the unique characteristics of CD62L T cells and their potential applications in clinical hematopoietic cell transplantation. [Blood] Abstract

Dual Action of TGF-β Induces Vascular Growth In Vivo through Recruitment of Angiogenic VEGF-Producing Hematopoietic Effector Cells

Scientists discovered a dual action mechanism by which transforming growth factor (TGF)-β promotes angiogenesis in vivo via recruitment of paracrine vascular endothelial growth factor (VEGF)-expressing hematopoietic effector cells. This mechanism may activate vascular growth and remodeling during inflammatory conditions and tumor growth when TGF-β activity is upregulated. [Angiogenesis] Abstract

Activation of Wnt/β-Catenin Signaling Induces Mitochondrial-Mediated Apoptosis in Hematopoietic Progenitor Cells
Researchers demonstrated that conditional expression of an active form of β-catenin in vivo induces a marked increase in the frequency of apoptosis in hematopoietic stem/progenitor cells. [J Biol Chem]
Full Article

Bmi1 Confers Resistance to Oxidative Stress on Hematopoietic Stem Cells
Researchers demonstrated that overexpression of Bmi1 confers resistance to stresses, particularly oxidative stress, onto hematopoietic stem cells. This thereby enhances their regenerative capacity and suggests that Bmi1 is located downstream of reactive oxygen species signaling and negatively regulated by it. [PLoS One] Full Article

Control of Human Hematopoietic Stem/Progenitor Cell Migration by the Extracellular Matrix Protein Slit3
The results of this study support a role for Slit3 in human hematopoietic stem and progenitor cell (HSPC) migration in vitro and homing in vivo and might contribute to the design of future approaches aimed at improving transplantation efficiency of human CD34+ HSPCs. [Lab Invest] Abstract


Anti-Thymocyte Globulin for Conditioning in Matched Unrelated Donor Hematopoietic Cell Transplantation Provides Comparable Outcomes to Matched Related Donor Recipients
Scientists concluded that the administration of anti-thymocyte globulin to patients undergoing unrelated donor hematopoietic cell transplantation (HCT) preserves the anti-leukemia benefit of the transplant, while reducing the risk of developing GvHD, resulting in OS rates that are comparable to matched related donor HCT recipients. [Bone Marrow Transplant] Abstract

Prognostic Factors Influencing Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation following Imatinib-Based Therapy in BCR-ABL-Positive ALL
Researchers investigated prognostic factors for the clinical outcome of allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) following imatinib-based therapy. [Blood Cancer J] Full Article

See Our Case Study: Determine Which Species Is Best For Testing Your Class Of Compound


World’s First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal
Osiris Therapeutics Inc. announced that it has received market authorization from Health Canada to market its stem cell therapy Prochymal® (remestemcel-L) for the treatment of acute graft-vs-host disease in children. [Osiris Therapeutics, Inc.] Press Release

Markey Receives $6.25 Million to Study Deadly Blood and Bone Marrow Disease

The University of Kentucky Markey Cancer Center has received more than $6 million to study a deadly blood and bone marrow disease often caused by chemotherapy or radiation treatments. [University of Kentucky] Press Release

Gamida Cell Closes $10 Million E Financing Round Earmarked to Support the Global Commercialization of the Company’s Lead Product StemEx® for Leukemia and Lymphoma
The financing will be used to support the global commercialization of the company’s lead cell therapy product, StemEx, in development as an alternative therapeutic treatment for patients with blood cancers, such as leukemia and lymphoma, who can be cured by bone marrow transplantation but do not have a matched bone marrow donor. [Gamida Cell, Ltd.] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 16th International HLA and Immunogenetics Workshop (IHIW)
May 28-June 3, 2012
Liverpool, United Kingdom

Visit our events page to see a complete list of events in the hematopoietic community.


Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral Position – Hematopoietic Stem Cells and Leukemia (City of Hope National Medical Center)

Postdoctoral Position – Hematopoietic Stem Cell Research (University of Texas Southwestern Medical Center)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us